| Texto completo | |
| Autor(es): Mostrar menos - |
Almeida-Afonso, Rosa
[1, 2]
;
Finamor, Danilo
[2]
;
Fonseca, Luiz Augusto M.
[1]
;
Rocha Veiga, Ana P.
[1]
;
Monteiro, Mariana A.
[1]
;
Magri, Marcello
[1]
;
Duarte, Alberto J. S.
[1]
;
Casseb, Jorge
[1]
;
Clinicas, Hosp
;
Dermatol, Serv
;
LIM56, Fac Med
;
Paulo, Inst Med Tropical Sao
;
Paulo, Univ Sao
Número total de Autores: 13
|
| Afiliação do(s) autor(es): | [1] Univ Sao Paulo, Hosp Clin, Dept Dermatol, Fac Med, Sao Paulo, SP - Brazil
[2] Ctr Referencia IST AIDS, Sao Paulo, SP - Brazil
Número total de Afiliações: 2
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Brazilian Journal of Infectious Diseases; v. 25, n. 3 MAY-JUN 2021. |
| Citações Web of Science: | 0 |
| Resumo | |
ABSTRACT Hypovitaminosis D is now considered a pandemic, especially among more vulnerable populations and in HIV-infected subjects, with 80% presenting levels below 30 ng/mL. As there is no consensus on the more adequate dosage needed to correct such deficiency, the objective of this study was to evaluate 25 (OH) vitamin D supplementation in HIV-1 patients deficient of vitamin D. A total of 73 HIV-1-infected patients were included, drawn from a cohort of 435 patients; 37 patients were randomized to the active group, supplemented once a week with 50,000 UI vitamin D by mouth (group 1) and 36 to the placebo group (group 2). The study period ranged from June 2016 to September 2017. Variables involved in vitamin D metabolism and risk factors associated with hypovitaminosis were evaluated. The mean age was 45 years and 31.5 % were women. Vitamin D supplementation was effective in normalizing serum levels after six months in group 1 (mean 35 ng/mL compared to 21 ng/mL for the placebo group; p= 0.04). No patient reached blood levels considered toxic (>100 UI). Efavirenz use can negatively influence vitamin D levels and supplementation is necessary as a likely adjunct to improving CD4+ T cells, resulting in greater effectiveness of the treatment. A weekly oral dose of 50,000 IU of vitamin D was sufficient to normalize the vitamin deficiency, safely and with good adherence among persons living with HIV/AIDS in Brazil. (AU) | |
| Processo FAPESP: | 18/07239-2 - Incidência, fatores de risco, mecanismos patogênicos e prevenção de distúrbios neurocognitivos (HAND) entre indivíduos infectados com HIV-1 |
| Beneficiário: | Jorge Simao do Rosario Casseb |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |